Especially in pelvic floor surgery we use high risk medical products with sensitive structures. Good skills and standard procedures based on high level of evidence are needed. Women have an 11% lifetime risk of needing surgery for pelvic floor disorders and 1 of 3 patients requiring additional surgery for prolapse or incontinence . More than 200 thousand surgical procedures for pelvic organ prolapse were undertaken in 1997 in the United States, at an estimated cost of more than $1 billion [2,3]. However there is a lack of homogenity and long-term data for the materials and techniques utilized. Additionally, no generally accepted definition for success after pelvic prolapse surgery exists. Outcome based on anatomic success only has a weak or absent correlation with patient perception of outcome . Multiple questionnaires and definitions complicate the comparability of the studies. From 2008 on, the FDA released several reports on more than 1000 unexpected and severe adverse events, associated with trans-vaginal placement of surgical mesh. It took 8 more years that FDA finally required premarket approval and postmarket surveillance studies for trans-vaginal meshes . FDA started to collaborate with the international expert group IDEAL in order to establish new requirements following the IDEAL-recommendations .
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
There are four main outcomes, which have been considered for the definition of success [7,8]:
- Patient satisfaction and impact on health-related quality of life;
- Anatomical reposition;
- Avoidance of complications.
Written By: Dimitri Barski, MD, Department of Urology, Lukas Hospital Neuss, Germany; Thomas Otto, MD, Department of Urology, Lukas Hospital, Neuss, Germany
1. Olsen AL, Smith VJ, Bergstrom JO, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol. 1997;89(4):501–506. doi: 10.1016/S0029-7844(97)00058-6.
2. Brown JS, Waetjen LE, Subak LL, et al. Pelvic organ prolapse surgery in the United States, 1997. Am J Obstet Gynecol. 2002;186:712–716. doi: 10.1067/mob.2002.121897.
3. Subak LL, Waetjen LE, Eeden S, et al. Cost of pelvic organ prolapse surgery in the United States. Obstet Gynecol. 2001;98:646–651. doi: 10.1016/S0029-7844(01)01472-7.
4. Barber MD, Brubaker L, Nygaard I, et al. Pelvic floor disorders network: Defining success after surgery for pelvic organ prolapse. Obstet Gynecol. 2009;114(3):600–9. doi: 10.1097/AOG.0b013e3181b2b1ae.
5. FDA strengthens requirements for surgical mesh for the transvaginal repair of pelvic organ prolapse. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm479732.htm. Accessed 25 Apr 2017.
6. McCulloch P, Altman DG, Campbell WB, et al. No surgical 357 innovation without evaluation: the IDEAL recommendations. Lancet. 2009;374(9695):1105-12. doi:10.1016/S0140-6736(09)61116-8.
7. Lee U, Raz S. Emerging concepts for pelvic organ prolapse surgery: What is cure? Curr Urol Rep. 2011 Feb;12(1):62-7. doi: 10.1007/s11934-010-0160-2.
8. Mearini L, Zucchi A, Nunzi E, Di Biase M, Bini V, Costantini E. The S.A.C.S. (Satisfaction-Anatomy-Continence-Safety) score for evaluating pelvic organ prolapse surgery: a proposal for an outcome-based scoring system. Int Urogynecol J. 2015;26(7):1061-1067.376 doi:10.1007/s00192-015-2655-3.
Read the Abstract